Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Doctors use three markers to help define breast cancers and guide treatment. One of those is the HER2 protein. The other two are hormone receptors (HR). When a cancer has none of these ...

BAMF Health in Grand Rapids has launched a study to identify markers for targeted breast cancer therapies using PET scans.

I think in HER2+ breast cancer, it's much easier to do ... for a second opinion because they had had a circulating tumor marker, whether it was CEA, CA 15-3, or CA 27-29, that was above normal.

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.

Systemic therapy is the main stay of management for metastatic breast cancer patients. Treatment is tailored to the tumor biology, hormone receptor status, HER2 expression and genetic markers like ...

You have a critical role in determining your breast cancer treatment plan. Here’s how you can work with your doctor. According to the National Cancer Institute, hormone receptor–positive (HR ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...

Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...